Flow Neuroscience is showcasing FL-100 at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
This is FL-100's coming-out party for US psychiatrists — FDA approved January 2026, launching Q2 2026. They need to build prescriber confidence in an entirely new treatment modality. At APA, they'll be demoing the device, presenting PSYLECT trial data (58% remission at 10 weeks), and educating psychiatrists on the prescription/reimbursement model. Price point is $500-800 — accessible compared to TMS.
Ask about: Prescriber workflow — how does a psychiatrist prescribe, monitor, and bill for at-home tDCS?; Payer/reimbursement strategy and CPT coding; PSYLECT trial durability data; patient selection criteria (who's the ideal FL-100 patient?); how they see it fitting into treatment algorithms (after failed SSRI? alongside medication?); planned indication expansions (TBI, anxiety, PTSD, addiction); competitive positioning vs. clinic-based TMS. Natural partnership opportunity — complementary digital technologies.
Perfect complement to Videra. VoiceVitals + ePRO+ provide continuous objective symptom tracking for FL-100 patients at home — neither Flow nor any tDCS device has a built-in behavioral outcome measure. Co-development opportunity: combined digital biomarker + neuromodulation evidence generation. Joint publication potential demonstrating that paired tDCS + continuous AI monitoring improves outcomes. For future indications (TBI, anxiety, PTSD), Videra's multimodal assessment adapts across all of them.
Set up a follow-up with Flow Neuroscience's team and Videra Health.
Email Ryan Roberts →